# DALY 2-EU (NCT04844866)

> Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04844866
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Miltenyi Biomedicine GmbH
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: MB-CART2019.1; Standard of Care
- Enrollment: 213
- Primary outcome: Part I: Event-free survival
- Primary outcome: Part II: Best objective response rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 7
- Podcasts: 3
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=daly-2-eu-nct04844866

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04844866", "email": "<work email>"}; the inbox owner confirms by the emailed link.